glp 1 agonist and weight loss Reduction with GLP-1 Agonists Paths for Discontinuation While Maintaining Weight GLP-1 Agonists: A Comprehensive Overview

11 Amorim Moreira Alves, G., Teranishi, M., Teixeira de Castro Gonalves Ortega, A

Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A, SURMOUNT-1 Investigators (2022) Tirzepatide once weekly for the treatment of obesity

Top Research Studies on GLP-1s and Cardiovascular Outcomes The November 2023 issue of The New England Journal of Medicine shared results from a research study (SELECT) involving 17,000 patients that showed the use of semaglutide was linked to a 20% reduction in the risk of major adverse cardiovascular events such as heart disease, stroke and peripheral arterial disease in patients who had previously been diagnosed with heart disease

The lowest effective dose isn't the lowest possible dose

Bifidobacterium plays a protective role in TNF--induced inflammatory response in Caco-2 cell through NF-B and p38MAPK pathways

If recurrent urticaria appears shortly after injections, clinicians should weigh the risks and benefits of continuing therapy